-
Enoblituzumab: Unveiling the Role of Anti-B7-H3 in Cancer Research(Post)
Key Facts About EnoblituzumabWhat is Enoblituzumab?Enoblituzumab is a monoclonal antibody targeting the B7-H3 protein, which is expressed on the surface of various cancer cells, includin
Annexin V Assays(Page)Annexin V Apoptosis Assay Kits | Flow Cytometry Detection | Assay Genie
Hemocytometer Cell Counting Procedure(Post)Cell Culture · ProtocolsHaemocytometer Cell Counting: Procedure, Calculation and Common ErrorsA haemocytometer turns a known chamber volume into a cell concentration, and the whole method rests on fou
Non-Small Cell Lung Carcinoma: Understanding, Diagnosing, and Treating NSCLC(Post)Non-Small Cell Lung Carcinoma (NSCLC) is the most common type of lung cancer, representing about 85% of all lung cancer cases. NSCLC includes several subtypes, with distinct biological ch
Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo
Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy(Post)Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
Co-Inhibitory Checkpoints Beyond PD-1: CTLA-4, LAG-3 and TIM-3(Post)PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are
Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and in
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune
Milatuzumab: Unveiling Its Role in Cancer Immunotherapy and Research(Post)What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W
B-Cell Receptor Signalling and the Germinal Centre Reaction(Post)The germinal centre is where antibody quality is made. A naive B cell that binds antigen does not become a source of protective, high-affinity IgG by accident. It passes through a tightly choreograph
Basiliximab: Mechanism, Clinical Applications, and Research Advancements(Post)Quick Facts About BasiliximabWhat is Basiliximab?Basiliximab is a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, primarily used to prevent organ transplant rejectio
Tunel 1-Step Assay Kits(Page)TUNEL Assay Kits | 1-Step In Situ Apoptosis Detection | Assay Genie
Deciphering B Cell Cancers With a Rituximab Biosimilar(Post)The fight against B cell cancers, a challenging spectrum of hematologic malignancies, has entered a new era with the introduction of rituximab biosimilars. These biosimilars promise to extend the
Validated GeniePlex Panels - Customer Applications(Page) Interactive Pathway Diagrams(Page) Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation(Post)What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect